Zepp Health Corporation
Revenue Dip, Cost-Cutting Success, Eyeing H2 Recovery
Published: 8/26/2024
Author: FRC Analysts
Sector: Technology | Industry: Consumer Electronics
Ticker Symbols:
ZEPP - NYSE 🔹
Rating and Key Data
| Metrics | Value |
|---|---|
| Current Price | US $0.73 |
| Fair Value | US $4.17 |
| Risk | 3 |
| Week Range | US $0.52-2.10 |
| Shares O/S (M) | 59 |
| Market Cap. (M) | US $43 |
| Current Yield (%) | N/A |
| P/E (forward) | N/A |
| P/B | 0.1 |
- In Q2-2024, revenue was down 56% YoY, missing our estimate by 22% due to lower than anticipated unit sales. EBITDA remained negative, but improved due to higher gross margins, and lower operating expenses.
- Revenue declined due to the discontinuation of several low-margin products, with new product launches skewed toward H2-2024, combined with softer global demand for smartwatches, and stronger competition.
Rating and Key Data
| Metrics | Value |
|---|---|
| Current Price | US $0.73 |
| Fair Value | US $4.17 |
| Risk | 3 |
| Week Range | US $0.52-2.10 |
| Shares O/S (M) | 59 |
| Market Cap. (M) | US $43 |
| Current Yield (%) | N/A |
| P/E (forward) | N/A |
| P/B | 0.1 |
